Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ValiRx puts convertible loan note facility with Yorkville to bed

ValiRx confirms that there are no further obligations existing between itself and Yorkville
Bank roll
The company's issued share capital will comprise of 399mln shares on admission of the 25.2mln shares to YA II.

Cancer therapeutics specialist ValiRx Plc (LON:VAL) said its standby equity distribution agreement with Yorkville (YA) is now done and dusted.

YA elected to convert all remaining US$520,000 of its convertible loan notes from the second tranche of its loan facility into 25.2mln ValiRx shares at a conversion price of 1.5429p a share.

No further amounts on Tranche 2 of the convertible loan notes (CLNs) remain outstanding. As previously announced Tranches 1 and 3 have been fully repaid and so this is the final conversion under the CLN facility.  

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use